Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith clinical programs — 34 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

GSK Glaxo Smith projects

34 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

34 programs

Clinical programs

  1. 208850

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  2. 209626 (DreaMM 12)

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  3. 209627(DREAMM 13)

    GlaxoSmithKline

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  4. 209664

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  5. 213406

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule active

    1 trial

  6. 217228

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  7. 219728

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial

  8. 219729

    GlaxoSmithKline

    Mild Asthma

    phase 1 other active

    1 trial

  9. 220104

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  10. 221362

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  11. 221377

    GlaxoSmithKline

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  12. 221458

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  13. 221531

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  14. 221615

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  15. 222110

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  16. 222261

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  17. 222778

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  18. 300134

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  19. 300163

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  20. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  21. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  22. Chloroquine

    GlaxoSmithKline

    Malaria

    phase 1 small molecule completed

    1 trial

  23. Daprodustat 2 mg tablet

    GlaxoSmithKline

    Anaemia

    phase 1 small molecule completed

    1 trial

  24. GSK2269557 ELLIPTA DPI

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  25. GSK2879552

    GlaxoSmithKline

    Leukaemia, Myelocytic, Acute

    phase 1 small molecule terminated

    1 trial

  26. GSK525762

    GlaxoSmithKline

    Solid Tumours

    phase 1 small molecule terminated

    1 trial

  27. GSK5533524

    GlaxoSmithKline

    Neoplasms

    phase 1 small molecule active

    1 trial

  28. Lamivudine

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 small molecule completed

    1 trial

  29. New formulation

    GlaxoSmithKline

    Herpes Labialis

    phase 1 small molecule completed

    1 trial

  30. Pazopanib

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 1 small molecule completed

    1 trial

  31. Poliorix

    GlaxoSmithKline

    Poliomyelitis

    phase 1 mab completed

    1 trial

  32. Prednisolone

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  33. SB-659032

    GlaxoSmithKline

    Atherosclerosis

    phase 1 small molecule completed

    1 trial

  34. Test Montelukast

    GlaxoSmithKline

    Respiratory Disorders

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.